by Richard Daverman, PhD
June 9, 2012 -- Mindray Medical paid $35.5 million for a controlling stake in Wuhan Dragonbio Surgical Implant, an orthopedics implant maker; Chongqing Zhifei Biological Products and Merck expanded their vaccine partnership to include Merck’s rotavirus vaccine; four clinical-stage CROs, one each from China, Japan, South Korean and Taiwan, have banded together to form the Alliance for Pacific Asia Clinical Trials (A-PACT); ShangPharma and Eli Lilly celebrated ten years of drug development partnership; WuXi PharmaTech reported that a former China employee has been convicted for the theft of chemical compounds; India is considering taking steps to reduce its dependence on APIs and intermediates from China; and Hutchison MediPharma released positive Phase I data for its two most advanced anti-cancer drugs. More details….
Stock Symbols: (NYSE: MR) (SHE: 300122) (NYSE: MRK) (NYSE: SHP) (NYSE: LLY) (NYSE: WX) (AIM: CHM)
